Kyverna (KYTX) Sees Pre-Market Surge After Regulatory Milestone
Shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) are experiencing notable momentum on the US stock charts today, following a pivotal regulatory approval. As of the latest pre-market check, KYTX stock has risen 8.78% to $10.78. RMAT Designation and Its Implications Kyverna Therapeutics (KYTX) reported that its KYV-101 has received Regenerative Medicine Advanced Therapy (RMAT) classification […]
Kyverna (KYTX) Sees Pre-Market Surge After Regulatory Milestone Read More »